Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CYDY CytoDyn	$0.27 +3.5%	$0.30	$0.10 ▼ $0.49	$325.55M	1.23	1.40 million shs	1.11 million shs
PAHC Phibro Animal Health	$30.57 -1.3%	$27.44	$16.16 ▼ $31.80	$1.25B	0.8	266,358 shs	195,038 shs
XERS Xeris Biopharma	$7.30 +0.3%	$5.16	$2.48 ▼ $7.61	$1.18B	0.65	3.04 million shs	2.19 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+2.02%
CYDY CytoDyn	+3.31%	+2.52%	-13.16%	-31.08%	+105.82%
PAHC Phibro Animal Health	-1.26%	+11.86%	+0.03%	+27.38%	+75.79%
XERS Xeris Biopharma	+0.34%	+10.61%	+38.00%	+49.59%	+186.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CYDY CytoDyn	0.3168 of 5 stars	0.0	2.0	0.0	0.0	1.1	0.0	1.3
PAHC Phibro Animal Health	3.7022 of 5 stars	0.9	2.0	2.5	1.1	3.3	3.3	2.5
XERS Xeris Biopharma	3.4213 of 5 stars	1.4	3.0	0.0	4.2	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
CYDY CytoDyn	0.00	N/A	N/A	N/A
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-20.18% Downside
XERS Xeris Biopharma	2.83	Moderate Buy	$6.58	-9.82% Downside

Current Analyst Ratings Breakdown

Latest CYDY, CALT, XERS, and PAHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	XERS Xeris Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
CYDY CytoDyn	N/A	N/A	$0.00 per share	77.91	($0.08) per share	N/A
PAHC Phibro Animal Health	$1.02B	1.22	$2.09 per share	14.65	$6.34 per share	4.82
XERS Xeris Biopharma	$203.07M	5.80	N/A	N/A	($0.12) per share	-60.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
CYDY CytoDyn	$3.74M	$0.01	26.89	∞	N/A	N/A	N/A	-4.40%	10/13/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	39.19	14.56	0.52	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
XERS Xeris Biopharma	-$54.84M	-$0.21	N/A	N/A	N/A	-13.01%	N/A	-8.00%	N/A

Latest CYDY, CALT, XERS, and PAHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	Q4 2025	PAHC Phibro Animal Health	$0.52	N/A	N/A	N/A	$362.24 million	N/A
8/7/2025	Q2 2025	XERS Xeris Biopharma	-$0.03	-$0.01	+$0.02	-$0.01	$64.58 million	$67.71 million
7/25/2025	Q4 2025	CYDY CytoDyn	N/A	-$0.01	N/A	-$0.01	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.57%	N/A	61.54%	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Latest CYDY, CALT, XERS, and PAHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	PAHC Phibro Animal Health	quarterly	$0.12	1.71%	9/3/2025	9/3/2025	9/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
CYDY CytoDyn	N/A	0.25	0.25
PAHC Phibro Animal Health	2.67	2.91	1.23
XERS Xeris Biopharma	N/A	1.95	1.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALT Calliditas Therapeutics AB (publ)	2.83%
CYDY CytoDyn	5.06%
PAHC Phibro Animal Health	99.34%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
CALT Calliditas Therapeutics AB (publ)	2.20%
CYDY CytoDyn	0.54%
PAHC Phibro Animal Health	50.07%
XERS Xeris Biopharma	6.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
CYDY CytoDyn	20	1.25 billion	1.25 billion	Not Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
XERS Xeris Biopharma	290	161.48 million	151.03 million	Optionable

CYDY, CALT, XERS, and PAHC Headlines

Recent News About These Companies

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Sells $309,400.00 in Stock

August 14 at 7:54 AM | insidertrades.com

Xeris Biopharma (NASDAQ:XERS) Rating Increased to Buy at HC Wainwright

August 14 at 2:13 AM | americanbankingnews.com

Xeris Biopharma's (XERS) "Buy" Rating Reaffirmed at HC Wainwright

August 13 at 8:35 AM | marketbeat.com

Informed Momentum Co LLC Grows Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

August 13 at 6:27 AM | marketbeat.com

Xeris Biopharma assumed with a Buy at H.C. Wainwright

August 12 at 5:49 PM | msn.com

Xeris Biopharma (XERS) Upgraded to Buy: Here's Why

August 12 at 1:01 PM | zacks.com

Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run?

August 12 at 10:16 AM | zacks.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is Knott David M Jr's 7th Largest Position

August 12 at 8:17 AM | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Raised to Strong-Buy at Wall Street Zen

August 11, 2025 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Releases Earnings Results, Beats Expectations By $0.02 EPS

August 10, 2025 | marketbeat.com

Critical Survey: Xeris Biopharma (NASDAQ:XERS) versus CASI Pharmaceuticals (NASDAQ:CASI)

August 10, 2025 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Upgraded to "Strong-Buy" at Wall Street Zen

August 10, 2025 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Sees Strong Trading Volume After Better-Than-Expected Earnings

August 10, 2025 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Sees Strong Trading Volume Following Better-Than-Expected Earnings

August 9, 2025 | marketbeat.com

Xeris Biopharma Holdings Second Quarter 2025 Earnings: Beats Expectations

August 9, 2025 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High After Earnings Beat

August 9, 2025 | americanbankingnews.com

Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High After Strong Earnings

August 8, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

August 7, 2025 | zacks.com

Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates

August 7, 2025 | zacks.com

Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance

August 7, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYDY, CALT, XERS, and PAHC Company Descriptions

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 08/12/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

CytoDyn OTCMKTS:CYDY

$0.27 +0.01 (+3.47%)

As of 08/14/2025 03:59 PM Eastern

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Phibro Animal Health NASDAQ:PAHC

$30.57 -0.39 (-1.26%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$30.78 +0.20 (+0.67%)

As of 08/14/2025 06:50 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Xeris Biopharma NASDAQ:XERS

$7.30 +0.02 (+0.27%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$7.31 +0.01 (+0.14%)

As of 08/14/2025 07:40 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time